For Investors

Close

Incyte International Locations

NORTH AMERICA—
HEADQUARTERS

FINLAND

JAPAN

SWEDEN

EUROPE—
HEADQUARTERS

FRANCE

THE NETHERLANDS

SWITZERLAND

AUSTRIA

GERMANY

NORWAY

UNITED KINGDOM

DENMARK

ITALY

SPAIN

Home > 网络加速器

雷霆每天免费2小时-雷霆加速下载器官网-雷霆加速破解版永久-雷霆每天免费2小时

雷霆每天免费2小时-雷霆加速下载器官网-雷霆加速破解版永久-雷霆每天免费2小时

雷霆每天免费2小时-雷霆加速下载器官网-雷霆加速破解版永久-雷霆每天免费2小时

Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.

雷霆每天免费2小时-雷霆加速下载器官网-雷霆加速破解版永久-雷霆每天免费2小时

Upcoming

Monday August 3, 2024 at 8:00 AM EDT
Monjuvi (tafasitamab-cxix) FDA approval

Tuesday August 4, 2024 at 8:00 AM EDT
Q2 2024 Incyte Corporation Earnings Conference Call

雷霆每天免费2小时-雷霆加速下载器官网-雷霆加速破解版永久-雷霆每天免费2小时

View All Events

手机网络加速器免费

Monday April 6, 2024 at 8:00 AM EDT
江苏一网吧为吸引学生上网 安装翻墙软件被查处_央广网 - cnr.cn:2021-12-9 · 网络安监员反电信诈骗:3年几乎没睡过几次好觉,数万元被骗、假冒淘宝客服、接警地浙江湖州、受害人是新手卖家，几条线索摆在眼前。诈骗过程很 ...

View All Events

Press Releases

网络加速器

FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)


sub免费网络加速器

Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints


July 16, 2024

Incyte to Report Second Quarter Financial Results


View All Releases

雷霆每天免费2小时-雷霆加速下载器官网-雷霆加速破解版永久-雷霆每天免费2小时

Michael Booth D.Phil
Division VP, Investor Relations & Corporate Responsibility
Phone: 302.498.5914
mbooth@incyte.com

Lauren Ayala, MBA
Senior Director, Investor Relations & Corporate Responsibility
Phone: 302.498.6141
layala@incyte.com

Christine Chiou
Senior Director, Investor Relations
Phone: 302.274.4773
cchiou@incyte.com

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Annual Reports

免费全球加速器 网络加速器

Quarterly Reports

雷霆每天免费2小时-雷霆加速下载器官网-雷霆加速破解版永久-雷霆每天免费2小时


All Press Releases

All Events

All SEC Filings